ClinicalTrials.gg
RecruitingNCT06681233Updated Mar 13, 2026

Feasibility Study of CBCT for IGRT in Cancer Patients

An interventional study of Comparison of HyperSight CBCT imaging to conventional CBCT imaging. in Head and Neck Cancers, Breast Cancer and Thoracic Cancers, sponsored by Varian, a Siemens Healthineers Company. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Varian, a Siemens Healthineers Company (part of Siemens Healthineers) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Head and Neck Neoplasms by Siemens Healthineers — 1 open to participants now, 3 under way, none of them phase 3. Head and Neck Neoplasms · Siemens Healthineers.

Planned enrollment
Largest of 11
50 · median 40
Started
2025
the only one that year
No phase
6 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Head and Neck Neoplasms by Siemens Healthineers, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 6 with no phase, and was the 12th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 12 studies in Head and Neck Neoplasms by Siemens Healthineers is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Head and Neck Neoplasms by Siemens Healthineers, or all of them as a file.
02

Study summary

Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.

Varian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.

This study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.

The goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.

03

Conditions studied

  • Head and Neck Cancers
  • Breast Cancer
  • Thoracic Cancers
  • Liver Cancer
  • Genito Urinary Cancer
  • Gastrointestinal Cancers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age ≥ 18
  2. Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal
  3. A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered

Exclusion criteria

Exclusion Criteria:

  1. Patient has Performance Status ≥3.
  2. Patient is wheelchair bound.
  3. Patient has a \<3 months.
  4. Patient is unwilling or unable to provide to participate in the study.
  5. Patient is pregnant or has plans for pregnancy during the period of treatment.
  6. Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HyperSight Imaging Arm

    Device: Comparison of HyperSight CBCT imaging to conventional CBCT imaging.

Interventions

  • DeviceComparison of HyperSight CBCT imaging to conventional CBCT imaging.

    Participants will receive their daily radiation treatment on a radiation therapy system equipped with HyperSight CBCT imaging. For at least 1 and up to 3 treatment fractions, participants will receive their daily radiation treatment on a system equipped with conventional CBCT imaging.

06

What researchers measure

Primary outcomes

  1. Comparison of Image Contrast Resolution

    The difference in contrast resolution will be evaluated between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process

    Time frame: End of radiation treatment at 9 weeks.

  2. Comparison of Image Uniformity

    The difference in image uniformity will be evaluated between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process.

    Time frame: End of radiation treatment at 9 weeks.

  3. Qualitative Image Comparison

    Qualitative comparison of HyperSight CBCT to conventional CBCT to determine preferred imaging for patient localization for daily treatment. Clinician observers will rank their preference using a 5-point Likert scale, where 1 represents strong preference of one imaging modality and 5 represents strong preference for the other modality.

    Time frame: End of radiation treatment at 9 weeks.

Secondary outcomes

  1. Reduction of Metal Artifacts

    In patients with a metal implant in the imaging field, the volume \[cubic centimeters\] of the metal artefact will be compared between a standard CBCT image, a CBCT image acquired using HyperSight technology, and a standard fan-beam CT acquired as part of the treatment simulation and planning process.

    Time frame: End of radiation treatment at 9 weeks.

  2. Imaging Time for Large Treatment Volumes

    For participants where multiple conventional CBCTs must be acquired and stitched together to capture the entire treatment field, the time \[seconds\] required for the overall imaging session will be recorded and compared between HyperSight CBCT and conventional CBCT.

    Time frame: End of radiation treatment at 9 weeks.

  3. Imaging Time for Breath Hold Imaging

    For participants who undergo breath-hold imaging, the time \[seconds\] required for the overall imaging session will be recorded and compared between HyperSight CBCT and conventional CBCT.

    Time frame: End of radiation treatment at 9 weeks.

  4. Patient Tolerance of Breath Hold Imaging

    For participants who undergo breath-hold imaging, the total number of individual breath-holds required for a complete image acquisition will be recorded and compared between HyperSight CBCT and conventional CBCT.

    Time frame: End of radiation treatment at 9 weeks.

  5. Feasibility of HyperSight CBCT for Treatment Planning

    For anatomical regions where there are limited anatomical deformations expected between image acquisitions, the radiation doses calculated for individual anatomical structures in a participant's treatment plan, which is based on their fan-beam simulation CT, will be compared to doses for the same structures after re-calculating the dose distribution for the same treatment plan using both the HyperSight CBCT and conventional standard CBCT.

    Time frame: End of radiation treatment at 9 weeks.

07

Study locations

4 of 4 sites recruiting
  • James Outpatient Center
    Columbus, Ohio 43210, United States
    Recruiting
  • Ohio State University, Brain and Spine Hospital
    Columbus, Ohio 43210, United States
    Recruiting
  • The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
    Columbus, Ohio 43210, United States
    Recruiting
  • Stefanie Spielman Comprehensive Breast Center
    Columbus, Ohio 43212, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2026, 18 months after the start.

Of 458 interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 8, 2024
StartActual
Feb 19, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Sep 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06681233
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Feb 19, 2025
Primary completion
Aug 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Mar 13, 2026

Study contacts

Sean Davidson
Contact
sean.davidson@varian.com
437-991-8294

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion